Since MET overexpression has either no impact on survival or is associated with inferior survival in NSCLC following surgery or chemotherapy [19,20,21,22,23,24], the improved survival is unique to ICI-treated patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.